{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T06:16:02Z","timestamp":1788243362530,"version":"build-2803163510"},"reference-count":24,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2014,12,1]],"date-time":"2014-12-01T00:00:00Z","timestamp":1417392000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,12,1]],"date-time":"2014-12-01T00:00:00Z","timestamp":1417392000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100015661","name":"UCB Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015661","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","epilepsybehavior.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Epilepsy & Behavior"],"published-print":{"date-parts":[[2014,12]]},"DOI":"10.1016\/j.yebeh.2014.09.074","type":"journal-article","created":{"date-parts":[[2014,10,27]],"date-time":"2014-10-27T00:15:59Z","timestamp":1414368959000},"page":"164-170","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":50,"special_numbering":"C","title":["Safety and efficacy of adjunctive lacosamide among patients with partial-onset seizures in a long-term open-label extension trial of up to 8 years"],"prefix":"10.1016","volume":"41","author":[{"given":"William","family":"Rosenfeld","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathan B.","family":"Fountain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gintaras","family":"Kaubrys","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elinor","family":"Ben-Menachem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cindy","family":"McShea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jouko","family":"Isojarvi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamela","family":"Doty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.yebeh.2014.09.074_bb0005","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1111\/j.1365-2753.2007.00821.x","article-title":"Open label extension studies and patient selection biases","volume":"14","author":"Hemming","year":"2008","journal-title":"J Eval Clin Pract"},{"key":"10.1016\/j.yebeh.2014.09.074_bb0010","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.eplepsyres.2008.04.007","article-title":"Reporting and analysis of open-label extension studies of anti-epileptic drugs","volume":"81","author":"Maguire","year":"2008","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.yebeh.2014.09.074_bb0015","series-title":"Vimpat\u00ae (lacosamide) tablets and injection [U.S. prescribing information]","year":"2014"},{"key":"10.1016\/j.yebeh.2014.09.074_bb0020","series-title":"Vimpat\u00ae (lacosamide) EPAR product information","year":"2014"},{"key":"10.1016\/j.yebeh.2014.09.074_bb0025","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1111\/j.1528-1167.2007.01188.x","article-title":"Efficacy and safety of oral lacosamide as adjunctive therapy in adults with partial-onset seizures","volume":"48","author":"Ben-Menachem","year":"2007","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2014.09.074_bb0030","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1111\/j.1528-1167.2009.02496.x","article-title":"Lacosamide as adjunctive therapy for partial-onset seizures: a randomized controlled trial","volume":"51","author":"Chung","year":"2010","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2014.09.074_bb0035","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1111\/j.1528-1167.2008.01951.x","article-title":"Adjunctive lacosamide for partial-onset seizures: efficacy and safety results from a randomized controlled trial","volume":"50","author":"Halasz","year":"2009","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2014.09.074_bb0040","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.2165\/11586830-000000000-00000","article-title":"Examining the clinical utility of lacosamide: pooled analyses of three phase II\/III clinical trials","volume":"24","author":"Chung","year":"2010","journal-title":"CNS Drugs"},{"key":"10.1016\/j.yebeh.2014.09.074_bb0045","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1111\/j.1528-1167.2012.03407.x","article-title":"Long-term safety and efficacy in patients with uncontrolled partial-onset seizures treated with adjunctive lacosamide: results from a Phase III open-label extension trial","volume":"53","author":"Husain","year":"2012","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2014.09.074_bb0050","first-page":"156","article-title":"Long-term adjunctive lacosamide in patients with uncontrolled partial-onset seizures: results from the SP774 phase III open-label extension trial","volume":"52","author":"Rosenow","year":"2011","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2014.09.074_bb0055","series-title":"Harkoseride: safety and tolerability of a new antiepileptic drug (AED) in patients with refractory partial seizures","year":"2000"},{"key":"10.1016\/j.yebeh.2014.09.074_bb0060","first-page":"433","article-title":"An open label, dose titration trial to evaluate tolerability and efficacy of oral SPM 927 as adjunctive therapy in patients with partial seizures","volume":"60","author":"Sachdeo","year":"2003","journal-title":"Neurology"},{"key":"10.1016\/j.yebeh.2014.09.074_bb0065","article-title":"Long-term adjunctive lacosamide in patients with uncontrolled partial-onset seizures: results from the SP774 phase III open-label extension trial","author":"Rosenow","year":"2014","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/j.yebeh.2014.09.074_bb0070","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1586\/14737175.9.1.33","article-title":"Lacosamide: pharmacology, mechanisms of action and pooled efficacy and safety data in partial-onset seizures","volume":"9","author":"Beydoun","year":"2009","journal-title":"Expert Rev Neurother"},{"key":"10.1016\/j.yebeh.2014.09.074_bb0075","first-page":"260","article-title":"Preliminary evaluation of the risk of cognitive adverse events in lacosamide clinical trials for adjunctive treatment of partial onset seizures","volume":"50","author":"Hebert","year":"2009","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2014.09.074_bb0080","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/0920-1211(94)90034-5","article-title":"The long-term safety and efficacy of gabapentin (Neurontin) as add-on therapy in drug-resistant partial epilepsy. The US Gabapentin Study Group","volume":"18","year":"1994","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.yebeh.2014.09.074_bb0085","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1046\/j.1528-1157.2003.54102.x","article-title":"Sustained efficacy and long-term safety of oxcarbazepine: one-year open-label extension of a study in refractory partial epilepsy","volume":"44","author":"Beydoun","year":"2003","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2014.09.074_bb0090","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1111\/j.1600-0404.2008.01055.x","article-title":"Long-term safety and efficacy of zonisamide in patients with refractory partial-onset epilepsy","volume":"118","author":"Wroe","year":"2008","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/j.yebeh.2014.09.074_bb0095","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1111\/j.1528-1167.2010.02532.x","article-title":"Long-term add-on pregabalin treatment in patients with partial-onset epilepsy: pooled analysis of open-label clinical trials","volume":"51","author":"Uthman","year":"2010","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2014.09.074_bb0100","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1111\/j.1528-1167.2010.02660.x","article-title":"Long-term efficacy and safety of eslicarbazepine acetate: results of a 1-year open-label extension study in partial-onset seizures in adults with epilepsy","volume":"51","author":"Halasz","year":"2010","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2014.09.074_bb0105","first-page":"263","article-title":"Perampanel Study 207: long-term open-label evaluation in patients with epilepsy","volume":"126","author":"Rektor","year":"2012","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/j.yebeh.2014.09.074_bb0110","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.eplepsyres.2012.05.007","article-title":"Safety and efficacy of ezogabine (retigabine) in adults with refractory partial-onset seizures: interim results from two ongoing open-label studies","volume":"102","author":"Gil-Nagel","year":"2012","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.yebeh.2014.09.074_bb0115","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.eplepsyres.2012.07.014","article-title":"Long-term safety and efficacy of eslicarbazepine acetate as adjunctive therapy in the treatment of partial-onset seizures in adults with epilepsy: results of a 1-year open-label extension study","volume":"103","author":"Hufnagel","year":"2013","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.yebeh.2014.09.074_bb0120","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1111\/j.1535-7511.2008.01283.x","article-title":"Driving issues in epilepsy: past, present, and future","volume":"9","author":"Krumholz","year":"2009","journal-title":"Epilepsy Curr"}],"container-title":["Epilepsy & Behavior"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525505014005265?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525505014005265?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T18:24:13Z","timestamp":1761503053000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525505014005265"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,12]]},"references-count":24,"alternative-id":["S1525505014005265"],"URL":"https:\/\/doi.org\/10.1016\/j.yebeh.2014.09.074","relation":{},"ISSN":["1525-5050"],"issn-type":[{"value":"1525-5050","type":"print"}],"subject":[],"published":{"date-parts":[[2014,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety and efficacy of adjunctive lacosamide among patients with partial-onset seizures in a long-term open-label extension trial of up to 8years","name":"articletitle","label":"Article Title"},{"value":"Epilepsy & Behavior","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.yebeh.2014.09.074","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}